Abstract

Enhancing the properties of advanced drug candidates is aided by the direct incorporation of specific chemical groups, avoiding the need to construct the entire compound from the ground up. Nevertheless, their chemical intricacy often poses challenges in predicting reactivity for C-H activation reactions and planning their synthesis. We adopted a reaction screening approach that combines high-throughput experimentation (HTE) at a nanomolar scale with computational graph neural networks (GNNs). This approach aims to identify suitable substrates for late-stage C-H alkylation using Minisci-type chemistry. GNNs were trained using experimentally generated reactions derived from in-house HTE and literature data. These trained models were then used to predict, in a forward-looking manner, the coupling of 3180 advanced heterocyclic building blocks with a diverse set of sp3-rich carboxylic acids. This predictive approach aimed to explore the substrate landscape for Minisci-type alkylations. Promising candidates were chosen, their production was scaled up, and they were subsequently isolated and characterized. This process led to the creation of 30 novel, functionally modified molecules that hold potential for further refinement. These results positively advocate the application of HTE-based machine learning to virtual reaction screening.

Late-stage functionalization of drug molecules can tune their properties without the need for entirely new syntheses, however, predicting reactivity and planning synthesis for late-stage C-H activation remains challenging. Here, the authors develop a reaction screening approach combining high-throughput experimentation with computational graph neural networks to identify suitable substrates that can be used for late-stage C-H alkylation via Minisci-type chemistry.

Details

Title
Identifying opportunities for late-stage C-H alkylation with high-throughput experimentation and in silico reaction screening
Author
Nippa, David F. 1   VIAFID ORCID Logo  ; Atz, Kenneth 2 ; Müller, Alex T. 3   VIAFID ORCID Logo  ; Wolfard, Jens 3   VIAFID ORCID Logo  ; Isert, Clemens 2   VIAFID ORCID Logo  ; Binder, Martin 3 ; Scheidegger, Oliver 3 ; Konrad, David B. 4   VIAFID ORCID Logo  ; Grether, Uwe 3   VIAFID ORCID Logo  ; Martin, Rainer E. 3   VIAFID ORCID Logo  ; Schneider, Gisbert 2   VIAFID ORCID Logo 

 F. Hoffmann-La Roche Ltd., Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland (GRID:grid.417570.0) (ISNI:0000 0004 0374 1269); Ludwig-Maximilians-Universität München, Department of Pharmacy, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X) 
 ETH Zurich, Department of Chemistry and Applied Biosciences, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780) 
 F. Hoffmann-La Roche Ltd., Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland (GRID:grid.417570.0) (ISNI:0000 0004 0374 1269) 
 Ludwig-Maximilians-Universität München, Department of Pharmacy, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X) 
Pages
256
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
23993669
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2894042696
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.